Received Jun 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (INFANRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | mf94h | — |
Administration in patient over the recommended age; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 11-year-old female patient who received DTPa (Infanrix) suspension for injection in pre-filled syringe (batch number mf94h with expiry date 06-MAR-2028) for prophylaxis. On 08-JUN-2026, the patient received the 2nd dose of Infanrix. On 08-JUN-2026, an unknown time after receiving Infanrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Administration in patient over the recommended age). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-JUN-2026 The healthcare professional called in to request data about the administration of Infanrix to a patient that was over the recommended age and requested recommendations on how to proceed.